DarioHealth Corp. (NASDAQ: DRIO) announced that its research portfolio now includes more than 100 peer‑reviewed scientific studies, encompassing journal publications and conference abstracts. The milestone, reached on January 21 2026, marks a significant expansion of the company’s evidence base and underscores its commitment to rigorous clinical validation.
The studies cover five chronic conditions—diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health—and are published in high‑impact venues such as the Journal of Medical Internet Research. They comprise independent, third‑party investigator‑initiated trials and longitudinal designs that run up to two years, providing robust data on real‑world outcomes rather than modeled projections.
Clinical outcomes reported in the portfolio are compelling: a 1.4 % reduction in HbA1c for diabetes, a 38 % drop in systolic blood pressure for hypertension, a 10 % decrease in BMI for weight management, a 60 % reduction in pain for musculoskeletal conditions, and 59 % and 48 % decreases in depression and anxiety, respectively. A JMIR‑published study estimated an average annual medical cost savings of $5,077 per user, illustrating tangible value for payers and self‑insured employers.
By achieving this depth of evidence, DarioHealth positions itself among the top tier of digital health vendors, a status that aligns with the growing demand from self‑insured employers, health plans, and payers for proven clinical and cost‑effectiveness. The multi‑condition platform, backed by a mature evidence base, supports the shift toward value‑based care and enhances the company’s ability to secure new client wins and deepen existing relationships.
Chief Medical Officer Omar Manejwala said, “For employers and health plans, evidence and scientific rigor are no longer optional – they are foundational. Crossing the 100‑study milestone demonstrates that Dario’s outcomes are durable, repeatable, and supported by a broad and credible body of scientific research.” Vice President of Clinical and Scientific Affairs Yifat Hershcovitz added, “Our focus on claims data and the link between behavior change and economic impact is what sets us apart in a crowded market.”
The 100‑study achievement is more than a numeric milestone; it is a strategic differentiator that reinforces DarioHealth’s value proposition in a market increasingly driven by data‑driven outcomes. The expanded evidence base is expected to accelerate client acquisition and strengthen existing partnerships, positioning the company for continued growth in the evolving digital health landscape.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.